Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company [Yahoo! Finance]